Abstracts Archive - Page 890 of 2607 - ACR Meeting Abstracts

Abstract Number: 0804 • ACR Convergence 2020
Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands
Elise van Mulligen¹, Saad Ahmed¹, Angelique Weel², Mieke Hazes³, Annette van der Helm - van Mil⁴ and Pascal de Jong¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Erasmus School of Health Policy & Management, Maasstad hospital, Erasmus MC, Rotterdam, Netherlands, ³Erasmus Medical Center, Rotterdam, Netherlands, ⁴Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Data on biological survival, stratified for discontinuation reasons, and predictors that influence survival time have not been explored extensively. Therefore, we aim to explore…
Abstract Number: 0805 • ACR Convergence 2020
The PROPER Study: Results of the First Interim Analysis of a Pan-EU Real-World Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Ulf Müller-Ladner¹, Karl Gaffney², Deepak Jadon³, Ulrich Freudensprung⁴ and Janet Addison⁵, ¹Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ²Norfolk and Norwich University Hospital NHS Foundation Trust, Norfolk, United Kingdom, ³Cambridge University Hospitals NHSFT, Cambridge, United Kingdom, ⁴Biogen International GmbH, Baar, Switzerland, ⁵Biogen Idec, Maidenhead, United Kingdom
Background/Purpose: SB5, an adalimumab biosimilar received EU marketing authorisation in August 2017, based on the totality of evidence from pre-clinical and clinical Phase I and…
Abstract Number: 0806 • ACR Convergence 2020
Identification and Adjustment for Factors Associated with Clinical Response in Rheumatoid Arthritis Clinical Trials to Improve Comparisons of Treatment Efficacy
Anthony Cordisco¹ and Joshua Baker¹, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Numerous clinical trials have been published in rheumatoid arthritis (RA), but comparing efficacies of disease-modifying anti-rheumatic drugs (DMARDs) is complicated by a lack of…
Abstract Number: 0807 • ACR Convergence 2020
Safety of Biologic & Targeted Therapies Among Elderly Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Akhil Sood¹, Soham Al Snih¹, Vijaya Murthy², Emilio Gonzalez¹ and Mukaila Raji¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch, League City, TX
Background/Purpose: Recent developments in biologic and targeted therapy have led to better control of disease activity and improved quality of life in patients with rheumatoid…
Abstract Number: 0808 • ACR Convergence 2020
Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta², Xiuying Li³, Edward C Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, Canada, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). TOFA can…
Abstract Number: 0809 • ACR Convergence 2020
Comparative Effectiveness of Intravenous Golimumab vs Dose-Escalated Infliximab in a Real World Population of Rheumatoid Arthritis Patients: 52-Week Data from the AWARE Study
Sergio Schwartzman¹, Shelly Kafka², Douglas Conaway³, Aaron Broadwell⁴, Shawn Black², Stephen Xu⁵, Wayne Langholff⁶ and Jeffrey R Curtis⁷, ¹Weill Cornell Medical College, New York, NY, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Grand Strand Regional Medical Center, Myrtle Beach, SC, ⁴Rheumatology and Osteoporosis Specialists, Shreveport, LA, ⁵Janssen Research & Development, LLC, Spring House, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is a Phase 4, prospective, noninterventional, observational, multicenter (88 sites), 3-year…
Abstract Number: 0810 • ACR Convergence 2020
Long Term Remission Rates from a Biologic Clinic: 12 Year Real World Data
Kieran Murray¹, Matthew Turk², Yousef Alammari², Francis Young³, Phil Gallagher⁴, Tajvur Saber⁵, Sinead Maguire⁶, Finbar O'Shea⁶, Ursula Fearon⁷ and Douglas Veale⁸, ¹Saint Vincent's University Hospital, Dublin 4, Dublin, Ireland, ²Saint Vincent's University Hospital, Dublin 4, Ireland, ³Saint Vincent's University Hospital, Dublin 4, ⁴St Vincents University Hospital, UCD, Dublin, Ireland, ⁵Peshawar Rheumatology Clinic, Dabgari Garden, Northern Areas, Pakistan, ⁶St James' Hospital, Dublin, Ireland, ⁷Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, ⁸EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland
Background/Purpose: Biologic therapies are widely used and greatly improve outcomes in RA and PsA. Yet, our ability to predict long-term remission and persistence remains limited.…
Abstract Number: 0811 • ACR Convergence 2020
Long-term Opioid Use in Patients with Rheumatoid Arthritis Treated with Sarilumab
Janet Pope¹, Amy Praestgaard², Hubert van Hoogstraten³, Melitza Iglesias-Rodriguez², Serge Perrot⁴, Yvonne Lee⁵, Anthony Sebba⁶ and Ernest Choy⁷, ¹Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ²Sanofi, Cambridge, MA, ³Sanofi, Bridgewater, NJ, ⁴Paris Descartes University, Paris, Ile-de-France, France, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Arthritis Associates, Palm Harbor, Tampa, FL, ⁷CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Prescription opioids are routinely used in patients with RA. However, use of opioids should be minimized to prevent abuse and addiction. Chronic opioid use…
Abstract Number: 0812 • ACR Convergence 2020
Real-World Utilization of Infliximab (IFX) and Its Biosimilars in Patients (Pts) with Rheumatoid Arthritis (RA) Since the First Biosimilar Approval in the US
Simon Helfgott¹, Janna Radtchenko², Nehad Soloman³, Kent Kwas Huston⁴, Jasvinder Singh⁵ and Colin Edgerton⁶, ¹BWH- HMS, Boston, MA, ²Trio Health, Louisville, CO, ³Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁴Kansas City Physician Partners, Kansas City, MO, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Articularis Healthcare, Summerville, SC
Background/Purpose: Biologics have revolutionized the treatment of autoimmune diseases, though costs and payer restrictions have limited who are treated and when these agents are used. …
Abstract Number: 0813 • ACR Convergence 2020
Treatment Outcomes in Patients with Seropositive versus Seronegative Rheumatoid Arthritis in Czech Registry ATTRA Treated with JAK Inhibitors
Karel Pavelka¹ and Zlatuše Křístková², ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
Background/Purpose: Seropositivity / seronegativity in RA may have influence on response to bDMARDs or tsDMARDs. There is incomplete knowledge of differences in efficacy of JAK…
Abstract Number: 0814 • ACR Convergence 2020
“I Want to Switch Back”: Real-world Experience of Switching Intravenous Abatacept and Tocilizumab to Subcutaneous Injection During the COVID-19 Pandemic
Rishi Gupta¹, Muhammad Shipa², Su-Ann Yeoh², Pauline Buck¹ and Michael Ehrenstein², ¹University College London Hospital, London, United Kingdom, ²University College London, LONDON, United Kingdom
Background/Purpose: During the COVID-19 pandemic, rapid guidelines by the National Institute for Health and Care Excellence (NICE) in the United Kingdom[1] recommended consideration of switching…
Abstract Number: 0815 • ACR Convergence 2020
Initial Pharmaceutical Management in a National Cohort of Elderly-Onset Rheumatoid Arthritis Patients
Deepan Dalal¹, Tingting Zhang², Hiren Varma² and Theresa Shireman², ¹Brown University, East Providence, RI, ²Brown University, Providence, RI
Background/Purpose: Methotrexate is the preferred initial drug for treatment of rheumatoid arthritis (RA) per American College of Rheumatology guidelines (2015). People with elderly-onset RA, classified as onset…
Abstract Number: 0816 • ACR Convergence 2020
Treat-to-target Strategy in Patients with Rheumatoid Arthritis in Daily Clinical Practice -still Underused, but Superior to Routine Care: A Propensity Score Matched Analysis from the ATTRA Registry
Jakub Závada¹ and Lucie Nekvindova², ¹Revmatologický ústav, Praha 2, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
Background/Purpose: Treat-to-target (T2T) is a widely accepted management strategy for RA. It recommends attaining a goal of at least low disease activity (LDA) within 6…
Abstract Number: 0817 • ACR Convergence 2020
Uptake of Janus Kinase Inhibitors for Management of Rheumatoid Arthritis in Australia
Geoffrey Littlejohn¹, Tegan Smith², Kathleen Tymms³, Peter Youssef⁴, Helen Cooley⁵, Sabina Ciciriello⁶, David Mathers⁷, Catherine OSullivan² and Hedley Griffiths⁸, ¹Monash Rheumatology, Clayton, VIC; OPAL Rheumatology Ltd, Sydney, NSW, Melbourne, Victoria, Australia, ²OPAL Rheumatology Ltd, Sydney, NSW, Kogarah, New South Wales, Australia, ³Canberra Rheumatology, Canberra, ACT, Canberra, Australian Capital Territory, Australia, ⁴University of Sydney, Sydney, NSW; Royal Prince Alfred Hospital, Camperdown, NSW, Camperdown, New South Wales, Australia, ⁵Hobart Private Hospital, Hobart, TAS, Taroona, Australia, ⁶Royal Melbourne Hospital, Melbourne, VIC, Melbourne, Victoria, Australia, ⁷Georgetown Rheumatology, Georgetown, NSW, Georgetown, New South Wales, Australia, ⁸Barwon Rheumatology Service, Geelong, VIC, Geelong, Victoria, Australia
Background/Purpose: JAK inhibitors (JAKi) are targeted synthetic DMARDs (tsDMARDs) with a different mode of action (MOA) to conventional synthetic and biologic DMARDs (cs and bDMARDs).…
Abstract Number: 0818 • ACR Convergence 2020
Efficacy and Safety of Switching Jakinibs in Rheumatoid Arthritis
Miriam Retuerto¹, Elisa Trujillo², Cristina Valero³, Cruz Fernández-Espartero⁴, Christian Soleto-Kharkovskaya⁵, Andrea García Valle⁶, Elena Aurrecoechea⁷, Marta Garijo⁸, Javier Loricera⁹ and Jose Luis Pablos¹⁰, ¹Hospital universitario 12 de octubre, Madrid, Spain, ²Hospital universitario de Canarias, Santa Cruz de Tenerife, Spain, ³Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ⁴H. Mostoles, Madrid, Spain, ⁵Gregorio Marañón University Hospital, Madrid, ⁶H. Palencia, Palencia, Spain, ⁷Hospital de Sierrallana, Torrelavega, Spain, ⁸Hospital de Sagunto, Valencia, Spain, ⁹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁰Hospital 12 de Octubre, Madrid, Spain
Background/Purpose: Different jakinibs have shown efficacy in rheumatoid arthritis (RA) but in an important proportion of patients, insufficient response leads to therapy withdrawal. The different…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].